Dapagliflozin versus sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction

• المؤلفون الرئيسيون: Ronen Arbel (مؤلف), Abed N. Azab (مؤلف), Mansi Oberoi (مؤلف), Enis Aboalhasan (مؤلف), Artyom Star (مؤلف), Khaled Elhaj (مؤلف), Fouad Khalil (مؤلف), Hilmi Alnsasra (مؤلف)
• التنسيق: كتاب
• منشور في: Frontiers Media S.A., 2024-03-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Background and aim:Heart failure with preserved ejection fraction (HFpEF) is associated with an increased risk of heart failure (HF) hospitalizations and cardiovascular death (CVD). Both dapagliflozin and sacubitril-valsartan have recently shown convincing reductions in the combined risk of CVD and...